Identification and characterization of stress degradation products of febuxostat employing ultra‐performance liquid chromatography‐ultraviolet/photodiode array and liquid chromatography–mass spectrometry/time‐of‐flight studies

Rationale Febuxostat (FEB) is a xanthine oxidase inhibitor approved by the U.S. Food and Drug Administration for long‐term treatment of gout and hyperuricemia. There were no reports on identification and characterization of stress degradation products of the drug. Methods FEB was subjected to forced...

Ausführliche Beschreibung